Ironwood Pharmaceuticals（IRWD）株式概要
バイオテクノロジー企業であるアイアンウッド・ファーマシューティカルズ社は、消化器（GI）疾患および希少疾患の治療薬の開発と商業化に米国内外で注力している。 詳細
IRWD Community Fair Values
Create NarrativeSee what 29 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ironwood Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$4.15 |
| 52週高値 | US$5.78 |
| 52週安値 | US$0.80 |
| ベータ | 0.21 |
| 1ヶ月の変化 | -5.25% |
| 3ヶ月変化 | -0.48% |
| 1年変化 | 415.53% |
| 3年間の変化 | -56.82% |
| 5年間の変化 | -70.19% |
| IPOからの変化 | -64.38% |
最新ニュース
ナラティブ更新 • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Seeking Alpha • Jul 13
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap
Summary Ironwood Pharmaceuticals (IRWD) faces a looming Linzess patent cliff in 2029, with generics poised to erode its main revenue stream. Apraglutide, acquired for $1B, is unlikely to fully offset Linzess losses due to mixed Phase 3 data, regulatory delays, and a small addressable market. Apraglutide’s risk-adjusted NPV is estimated at $461M, well below IRWD’s enterprise value, and further delays could reduce this value significantly. I initiate coverage with a cautious Hold, as IRWD appears cheap but justified by limited pipeline prospects and significant execution risks. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • Jul 21
IRWD: Pediatric Approval And 2026 Outlook Will Support Future Upside
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $10.00 to $11.00, citing updated assumptions for the discount rate, revenue growth, profit margins, and future P/E to support the new price target. What’s in the News for Ironwood Pharmaceuticals The U.S. FDA approved an expanded LINZESS (linaclotide) indication for pediatric patients 2 years and older with functional constipation, making it the only FDA approved prescription therapy specifically for pediatric functional constipation, according to company disclosures.Seeking Alpha • Jul 13
Ironwood: Linzess Buys Time, But Apraglutide's rNPV Doesn't Close The Gap
Summary Ironwood Pharmaceuticals (IRWD) faces a looming Linzess patent cliff in 2029, with generics poised to erode its main revenue stream. Apraglutide, acquired for $1B, is unlikely to fully offset Linzess losses due to mixed Phase 3 data, regulatory delays, and a small addressable market. Apraglutide’s risk-adjusted NPV is estimated at $461M, well below IRWD’s enterprise value, and further delays could reduce this value significantly. I initiate coverage with a cautious Hold, as IRWD appears cheap but justified by limited pipeline prospects and significant execution risks. Read the full article on Seeking Alpha
ナラティブ更新 • Jul 06
IRWD: Expanded Pediatric Use And Earnings Outlook Will Drive Upside Potential
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $4.85 to $6.10. This change reflects updated assumptions on the discount rate, revenue growth, profit margin, and future P/E levels.ナラティブ更新 • Jun 22
IRWD: Expanded Constipation Indication And 2026 Outlook Will Support Future Upside
Analysts have modestly revised their price target for Ironwood Pharmaceuticals to $10.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E. These revisions leave their fair value estimate unchanged at $10.00.
ナラティブ更新 • Jun 08
IRWD: Pediatric Expansion And Stable Guidance Will Support Future Upside Potential
Analysts have adjusted their $ price target on Ironwood Pharmaceuticals, reflecting updated assumptions for discount rate, revenue growth, profit margins, and future P/E, and are now framing the stock's valuation through a more measured growth outlook. What's in the News The U.S. FDA approved LINZESS (linaclotide) for functional constipation in pediatric patients 2 to 5 years old, expanding the prior indication that started at age 6 and keeping LINZESS as the only FDA approved prescription therapy for pediatric functional constipation, according to the company.ナラティブ更新 • May 25
IRWD: Maintained 2026 Revenue Outlook Will Support Long Term Cash Flows
Analysts have kept their price target for Ironwood Pharmaceuticals steady at $10.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E that they view as better aligned with the company’s current risk and earnings profile. What's in the News Chief Financial Officer Gregory Martini plans to resign effective May 15, 2026.分析記事 • May 11
Results: Ironwood Pharmaceuticals, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) came out with a strong set of quarterly numbers that could...ナラティブ更新 • May 01
IRWD: Earnings Outlook And Trial Updates Will Limit Future Share Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, citing updated assumptions for discount rate, revenue growth, profit margins, and future P/E, while keeping their fair value estimate broadly unchanged at $3.70. What's in the News Ironwood plans to present data from the LANDMARK survey at the 2026 Digestive Disease Week meeting in Chicago, highlighting healthcare professional views on the burden of total parenteral nutrition for short bowel syndrome and preferred attributes for new therapies that reduce dependence on parenteral support (company announcement).ナラティブ更新 • Apr 17
IRWD: Extended Revenue Guidance And Margin Assumptions Will Restrain Future Upside
Analysts have slightly adjusted their price target on Ironwood Pharmaceuticals, reflecting small tweaks to inputs such as discount rate, revenue growth assumptions, profit margin outlook and the future P/E multiple, while keeping their overall fair value estimate steady at $3.70. What's in the News Ironwood Pharmaceuticals reiterated its earnings guidance for 2026, stating that total revenue is expected to be in the range of $450 million to $475 million.ナラティブ更新 • Apr 02
IRWD: Multi Year Revenue Guidance And Margin Assumptions Will Shape Outlook
Analysts have raised their price target on Ironwood Pharmaceuticals by $3, reflecting updated assumptions around fair value, a lower discount rate, higher projected revenue growth, a materially stronger profit margin outlook, and a reduced future P/E multiple. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in the range of $450 million to $475 million (company guidance).ナラティブ更新 • Mar 19
IRWD: Reinforced 2026 Guidance And Legal Resolution Will Support Future Cash Flows
Analysts have modestly adjusted their price target on Ironwood Pharmaceuticals, now reflecting a $10.00 fair value that aligns with updated assumptions around the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News Ironwood Pharmaceuticals reiterated earnings guidance for 2026, with total revenue expected in a range of $450 million to $475 million.ナラティブ更新 • Mar 05
IRWD: Index Inclusion And Reinforced Guidance Will Support Future Cash Flows
Analysts have raised their fair value estimate for Ironwood Pharmaceuticals from $8.00 to $10.00, citing updated assumptions for revenue growth, profit margins, and future P/E expectations built into their models. What's in the News Ironwood Pharmaceuticals reiterated its 2026 earnings guidance, with total revenue expected in a range of $450 million to $475 million.ナラティブ更新 • Feb 19
IRWD: Medicare Pricing Clarity Will Support Future Cash Flows And Optionality
Analysts have raised their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing clearer visibility on future Linzess pricing after the Centers for Medicare and Medicaid Services set a negotiated $136 Medicare price for a 30 day supply. They view this as supportive of the company as it reviews alternatives.ナラティブ更新 • Feb 05
IRWD: Medicare Pricing Clarity And Revenue Outlook Will Shape Balanced Share Prospects
Ironwood Pharmaceuticals' analyst price target has moved higher, with the fair value estimate shifting from about US$2.50 to roughly US$4.85. Analysts cite updated revenue growth, profit margin and future P/E assumptions, along with recent Medicare pricing clarity for Linzess, as key drivers of their revised view.ナラティブ更新 • Jan 22
IRWD: Medicare Pricing Clarity Will Support Future Earnings And Deal Optionality
Narrative Update Overview Analysts have raised their price target for Ironwood Pharmaceuticals to US$3.80 from US$1.70, citing clearer visibility on future Linzess Medicare pricing following the recent Inflation Reduction Act negotiation outcomes. Analyst Commentary Bullish analysts are highlighting the recent Medicare pricing outcome for Linzess as an important input into their updated view on Ironwood Pharmaceuticals.ナラティブ更新 • Jan 07
IRWD: Medicare Price Certainty Will Support Stronger Earnings And Optionality
Analysts have lifted their 12 month fair value estimate for Ironwood Pharmaceuticals from $3.80 to $8.00, citing clearer Medicare pricing for Linzess and what they view as a stronger setup as the company reviews potential alternatives. Analyst Commentary Recent research has focused on how clearer Medicare pricing for Linzess could affect Ironwood Pharmaceuticals' valuation and options review.分析記事 • Jan 06
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Shares Bounce 32% But Its Business Still Trails The Industry
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have continued their recent momentum with a 32% gain in the last...ナラティブ更新 • Dec 13
IRWD: Medicare Pricing Clarity Will Support More Predictable Earnings And Balanced Outlook
Analysts have lifted their price target on Ironwood Pharmaceuticals to $3.80 from $1.70, citing improved visibility on Linzess Medicare pricing that supports higher long term profitability. This, they say, justifies a lower discount rate, a more stable revenue outlook, and a richer fair value assessment.ナラティブ更新 • Nov 28
IRWD: Future Share Price Could Weaken Amid Upcoming Medicare Price Cuts
Analysts have increased their price target for Ironwood Pharmaceuticals to $3.80 from $1.70. They cite greater clarity on future Medicare pricing and strategic opportunities following recent policy announcements.ナラティブ更新 • Nov 13
IRWD: Future Expectations May Not Justify Recent Share Price Levels
Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.分析記事 • Nov 12
Need To Know: Analysts Are Much More Bullish On Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Revenues
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders will have a reason to smile today, with the analysts making...分析記事 • Nov 06
There's No Escaping Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Muted Revenues Despite A 39% Share Price Rise
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...ナラティブ更新 • Oct 29
Worsening Revenue Outlook Will Limit Upside Despite Improving Profit Margins
Analysts have lowered their price target for Ironwood Pharmaceuticals from $0.95 to $0.95, citing reduced revenue growth expectations. This has been offset by improved profit margins and a lower discount rate.分析記事 • Sep 10
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 33% But Its Business Prospects Need A Lift Too
Despite an already strong run, Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shares have been powering on, with a gain...分析記事 • Jun 25
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Held Back By Insufficient Growth Even After Shares Climb 28%
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders are no doubt pleased to see that the share price has...分析記事 • Dec 21
Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) shareholders would be excited to see that the share price has had a...分析記事 • Oct 24
Lacklustre Performance Is Driving Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 1.6x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...
新しいナラティブ • Sep 17
LINZESS And Apraglutide Set To Power Through Market Challenges With Strong Growth Prospects
LINZESS prescription growth indicates strong market acceptance, potentially increasing revenue as it gains market share.分析記事 • Aug 16
Ironwood Pharmaceuticals (NASDAQ:IRWD) Is Posting Promising Earnings But The Good News Doesn’t Stop There
The market seemed underwhelmed by the solid earnings posted by Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) recently...分析記事 • Jun 27
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Looks Inexpensive But Perhaps Not Attractive Enough
You may think that with a price-to-sales (or "P/S") ratio of 2.4x Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ) is...Seeking Alpha • Jun 20
Ironwood Pharmaceuticals: Q3 Of 2024 Data Readout For PBC
Summary Ironwood Pharmaceuticals, Inc. data from the phase 2 proof-of-concept study, using CNP-104 for the treatment of patients with primary biliary cholangitis, expected in Q3 of 2024. The global primary biliary cholangitis therapeutics market size is projected to reach $1.4 billion by 2032. NDA filing and other regulatory filings across the globe of apraglutide for the treatment of patients with short bowel syndrome who are dependent on parenteral support. Ironwood Pharmaceuticals had cash and cash equivalents of $121.5 million as of March 31st of 2024; Enough cash to fund its operations for at least the next 12 months. Read the full article on Seeking Alpha株主還元
| IRWD | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 16.6% | 2.7% | 5.5% |
| 1Y | 415.5% | 37.6% | 20.8% |
業界別リターン: IRWD過去 1 年間で37.6 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: IRWD過去 1 年間で20.8 % の収益を上げたUS市場を上回りました。
価格変動
| IRWD volatility | |
|---|---|
| IRWD Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: IRWD 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: IRWDの 週次ボラティリティ ( 10% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1998 | 100 | Tom McCourt | ironwoodpharma.com |
バイオテクノロジー企業であるアイアンウッド・ファーマシューティカルズ・インク（Ironwood Pharmaceuticals, Inc.グアニル酸シクラーゼC型（GC-C）作動薬であるリナクロチドを、便秘を伴う過敏性腸症候群または慢性特発性便秘に苦しむ成人患者、および機能性便秘に苦しむ小児患者の治療薬として、「リンゼス」および「コンステラ」の名称で販売している。また、間質性膀胱炎／膀胱痛症候群や子宮内膜症を含む内臓痛の治療薬であるGC-C作動薬IW-3300、非経口栄養に依存する短腸症候群患者や急性移植片対宿主病の治療薬であるグルカゴン様ペプチド-2の合成ペプチド長時間作用型アナログであるアプラグルチドも開発している。アッヴィ社、アストラゼネカ社、アステラス製薬社とは、リナクロチドの開発および商業化に関して戦略的パートナーシップを結んでいる。以前はMicrobia, Inc.として知られていたが、2008年4月にIronwood Pharmaceuticals, Inc.に社名変更。アイアンウッド・ファーマシューティカルズ・インクは1998年に設立され、マサチューセッツ州ボストンに本社を置いている。
Ironwood Pharmaceuticals, Inc. 基礎のまとめ
| IRWD 基礎統計学 | |
|---|---|
| 時価総額 | US$709.48m |
| 収益（TTM） | US$102.18m |
| 売上高(TTM) | US$361.51m |
6.7x
PER（株価収益率1.9x
P/SレシオIRWD は割高か？
公正価値と評価分析を参照収益と収入
| IRWD 損益計算書（TTM） | |
|---|---|
| 収益 | US$361.51m |
| 売上原価 | US$89.64m |
| 売上総利益 | US$271.87m |
| その他の費用 | US$169.69m |
| 収益 | US$102.18m |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 06, 2026
| 一株当たり利益（EPS） | 0.62 |
| グロス・マージン | 75.20% |
| 純利益率 | 28.26% |
| 有利子負債／自己資本比率 | -269.3% |
IRWD の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/08/05 07:46 |
| 終値 | 2026/08/05 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Ironwood Pharmaceuticals, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26
| アナリスト | 機関 |
|---|---|
| Geoffrey Meacham | Barclays |
| Patrick Trucchio | Berenberg |
| David Maris | BMO Capital Markets Equity Research |